SlideShare a Scribd company logo
New Hollow Fiber Membranes for
AEX and CEX in Flow-Through Mode
Bixente MARTIRENE, MSc
Senior Product Manager
Asahi Kasei Bioprocess Europe
b.martirene@akbio.eu
8th Annual European BioInnovation Leaders Summit
10th - 11th February 2015
Radisson Blu Edwardian Hotel, London
www.ak-bio.com
1) Pathogen Removal Filters
Content
Introduction
1)  Hollow Fiber Membrane for AEX: QyuSpeed D
2)  Hollow Fiber Membrane Prototype for CEX
3)  Case study:
Combination of CEX Prototype & AEX QyuSpeed D
Conclusion
Foundation: 1931; HQ: Tokyo; Employees: 25 000; Turnover: 16 B$
Asahi Kasei Group
3
PlanovaTM
Virus removal filters
Asahi Kasei Bioprocess
4
PlanovaTM
Virus removal filters
QyuSpeedTM D
AEX adsorber
BioOptimalTM MF-SL
TFF microfilter
Asahi Kasei Bioprocess
5
PlanovaTM
Virus removal filters
QyuSpeedTM D
AEX adsorber
BioOptimalTM MF-SL
TFF microfilter
Systems & Equipment
Asahi Kasei Bioprocess
6
PlanovaTM
Virus removal filters
QyuSpeedTM D
AEX adsorber
BioOptimalTM MF-SL
TFF microfilter
Systems & Equipment
CellufineTM
Cellulose Beads
Chromatography media
(made by JMC Corporation)
Asahi Kasei Bioprocess
7
1) Pathogen Removal Filters
Introduction
9
Why Membrane vs. Resin ?
ü  Mass transfer: “fast” convection vs. “slow” diffusion
ü  5-13 BV*/min vs. 0.5-2 BV/min, low pressure drop
ü  10-20 x higher loading capacity ➔ smaller BV required
ü  Easy setup & operation ≈ Dead-End Filter
Introduction
* : Bed Volume = Column Volume = Membrane Volume
10
Introduction
Feedback from our customers:
ü  Flow-Through mode preferred for ease of use
ü  AEX adsorbers more & more implemented in DSP
ü  CEX mainly performed with classical resins
11
Introduction
Asahi Kasei BioProcess:
ü  QyuSpeed D launched in 2011 for AEX ➔ Success
ü  New Hollow Fiber Membrane for CEX in FT mode ???
1) Pathogen Removal Filters
1)  Hollow Fiber Membrane for AEX: QyuSpeed D
13
QyuSpeed D AEX Adsorber
Inlet
Outlet
QyuSpeed D
Module
14
QyuSpeed D AEX Adsorber
Inlet
Outlet
Hollow fiberQyuSpeed D
Module
Protein solution
with biomolecules -
Protein solution
biomolecules - free
§  Dead-End
filtration
§  Removal of
HCP, DNA,
Virus
15
QyuSpeed D AEX Adsorber
Inside the pore
Grafted chain with
DEA ligands
Biomolecules -
Micropore
0.2-0.3 µm
>
16
QyuSpeed D AEX Adsorber
Inside the pore
Grafted chain with
DEA ligands
Biomolecules -
Micropore
0.2-0.3 µm
H2C
C-C-O-CH2CHCH2H3C-
=
O HO
NH(CH2CH3)2
+
()
H2C
C-C-O-CH2CHCH2H3C-
=
O HO
()
NH(CH2CH3)2
+
Poly glycidyl methacrylate
Grafted chain
DEA
> >
17
QyuSpeed D AEX Adsorber
ü  Multipoint adsorption
ü  High ligand density
Inside the pore
Grafted chain with
DEA ligands
Biomolecules -
Micropore
0.2-0.3 µm
H2C
C-C-O-CH2CHCH2H3C-
=
O HO
NH(CH2CH3)2
+
()
H2C
C-C-O-CH2CHCH2H3C-
=
O HO
()
NH(CH2CH3)2
+
Poly glycidyl methacrylate
Grafted chain
DEA
➔ high DBC & Salt tolerance
> >
18
Product Line-Up
Membrane
(Bed)
Volume	
0.6 mL 150 mL 550 mL 5 L
Maximum
Flow Rate
8 mL/min 2 L/min 8 L/min 60 L/min
0.6 mL	 150 mL	 550 mL	 5 L	
1172 mm
315 mm
19
Innovative Implementation: pre Prot. A
1)  Post Protein A, in place of traditional AEX resin column
2)  Post CEX w/o any prior dilution or buffer change: salt tolerant
Protein A
UFPlanova
CIEX
Centri-
fugation
Tangential MF
Depth
Filtration
or
0.2 µm
filtration
20
AEX with
QyuSpeed D
Classical Implementations of QyuSpeed D
10% BSA DBC > 40 g/L-BV
10% DNA DBC @ 15 mS/cm < 30 g/L-BV
HCP reduction
25 – 99 % removal
(depending on pI of HCP)
Parvovirus LRV > 4 Log
MAb Loading capacity
Post Protein A
(in standard flow through mode)
> 2000 g/L-BV
(depending on quantities of impurities)
Number of regenerations
> 10
(tested up to 100 x with BSA)
21
Performances
22
Advantages vs. other AEX Adsorbers
ü  Same membrane for low or high conductivity solutions
ü  “flexible” implementation: pre or post Prot. A, pre or post CEX
ü  Single-use or Reusable (1M NaCl; 1N NaOH)
23
2)  Hollow Fiber Membrane Prototype for CEX
24
2)  Hollow Fiber Membrane Prototype for CEX
➔ CEX in FT mode
25
New QyuSpeed Prototype for CEX
Inlet
Lab module
Outlet
26
New QyuSpeed Prototype for CEX
Inlet
§  Flow Through
mode = Dead-
End filtration
§  Removal of
Aggregates,
Prot. A, HCP
Outlet
Lab module
27
New QyuSpeed Prototype for CEX
Inlet
Hollow fiber
Protein solution
with aggregates
Protein solution
aggregate free
Outlet
Lab module
§  Flow Through
mode = Dead-
End filtration
§  Removal of
Aggregates,
Prot. A, HCP
28
Inside the pore
Grafted chain with
3 different ligands
Aggregate
Micropore
0.2-0.3 µm
>
New QyuSpeed Prototype for CEX
29
Inside the pore
Grafted chain with
3 different ligands
Aggregate
Micropore
0.2-0.3 µm
Grafted chain
> >
New QyuSpeed Prototype for CEX
-R1
	
-R2	
-R3	
R1, R2 & R3 are side chains with different ligands & interactions
30
Aggregate Removal vs. pH
31
Aggregate Removal vs. pH
Feed solution: MAb (h-IgG1), 5 mg/mL, pI 8.4
Buffer: 15 mM Tris-HCl
Conductivity: 1.4 mS/cm
Loading: ~ 1 000 g/L-membrane volume (BV)
Flow rate: 6 BV/min
Aggregate content: ~ 5 %
32
Aggregate Removal vs. pH
Feed solution: MAb (h-IgG1), 5 mg/mL, pI 8.4
Buffer: 15 mM Tris-HCl
Conductivity: 1.4 mS/cm
Loading: ~ 1 000 g/L-membrane volume (BV)
Flow rate: 6 BV/min
Aggregate content: ~ 5 %
pH 7.0 pH 7.5 pH 8.0
Feed
solution	
Monomer (%) 94.73 94.51 93.54
Dimer (%) 2.25 2.76 3.58
≧ Trimer (%) 3.02 2.73 2.88
33
Aggregate Removal vs. pH
pH 7.0 pH 7.5 pH 8.0
34
Aggregate Removal vs. pH
pH 7.0 pH 7.5 pH 8.0
pH 7.0 pH 7.5 pH 8.0
Monomer recovery (%) 88.87 92.2 93.07
35
Aggregate Removal vs. pH
pH 7.0 pH 7.5 pH 8.0
pH 7.0 pH 7.5 pH 8.0
Monomer recovery (%) 88.87 92.2 93.07
Flow Through	
(reduction %)
Monomer (%) 97.42
Dimer (%) 1.34 (49)
≧ Trimer (%) 1.24 (65)
36
Aggregate Removal vs. pH
pH 7.0 pH 7.5 pH 8.0
pH 7.0 pH 7.5 pH 8.0
Monomer recovery (%) 88.87 92.2 93.07
Flow Through	
(reduction %)
Monomer (%) 97.42 98.65
Dimer (%) 1.34 (49) 1.10 (65)
≧ Trimer (%) 1.24 (65) 0.25 (92)
37
Aggregate Removal vs. pH
pH 7.0 pH 7.5 pH 8.0
pH 7.0 pH 7.5 pH 8.0
Monomer recovery (%) 88.87 92.2 93.07
Flow Through	
(reduction %)
Monomer (%) 97.42 98.65 97.98
Dimer (%) 1.34 (49) 1.10 (65) 1.74 (57)
≧ Trimer (%) 1.24 (65) 0.25 (92) 0.28 (91)
38
Aggregate Removal vs. pH
pH 7.0 pH 7.5 pH 8.0
pH 7.0 pH 7.5 pH 8.0
Monomer recovery (%) 88.87 92.2 93.07
Flow Through	
(reduction %)
Monomer (%) 97.42 98.65 97.98
Dimer (%) 1.34 (49) 1.10 (65) 1.74 (57)
≧ Trimer (%) 1.24 (65) 0.25 (92) 0.28 (91)
39
Aggregate Removal vs. Cond.
40
Aggregate Removal vs. Cond.
1.4 mS/cm 2.6 mS/cm 4.7 mS/cm
41
Conductivity (mS/cm)	 1.4 2.6 4.7
Monomer recovery (%) 88.87 92.32 89.12
Flow Through	
(reduction %)
Monomer (%) 97.42 99.48 98.59
Dimer (%) 1.34 (49) 0.39 (78) 1.03 (60)
≧ Trimer (%) 1.24 (65) 0.13 (95) 0.38 (86)
Aggregate Removal vs. Cond.
1.4 mS/cm 2.6 mS/cm 4.7 mS/cm
pH 7.0
42
Comments on the Performances
ü  Performances linked to pH & Cond. ➔ optimizations
ü  ~ 90 % monomer recovery (binding at the beginning)
ü  Up to 95 % aggregate removal possible
ü  > 1 000 g/L-BV loading capacity
➔ 10-20 x higher loading capacity vs. traditional CEX resin
1) Pathogen Removal Filters
3)  Case study:
Combination of CEX Prototype & AEX QyuSpeed D
44
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
AEX QyuSpeed D
(FT)
Clarification
CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL
45
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
AEX QyuSpeed D
(FT)
Clarification
CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL	
Elution buffer
25mM Acetate; pH 3.4
46
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
AEX QyuSpeed D
(FT)
Clarification
CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL	
Titration
pH 7.0	
Elution buffer
25mM Acetate; pH 3.4
47
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
AEX QyuSpeed D
(FT)
Aggregate
addition	
Clarification
CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL	
Titration
pH 7.0	
Elution buffer
25mM Acetate; pH 3.4
48
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
Loading: 1041 mg/mL-BV
MAb: 2.6 mg/mL
Flow rate: 6 BV/min
AEX QyuSpeed D
(FT)
Aggregate
addition	
Clarification
CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL	
Titration
pH 7.0	
Elution buffer
25mM Acetate; pH 3.4
49
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
Loading: 1041 mg/mL-BV
MAb: 2.6 mg/mL
Flow rate: 6 BV/min
Titration
pH 7.8
AEX QyuSpeed D
(FT)
Aggregate
addition	
Clarification
CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL	
Titration
pH 7.0	
Elution buffer
25mM Acetate; pH 3.4
50
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
Loading: 1041 mg/mL-BV
MAb: 2.6 mg/mL
Flow rate: 6 BV/min
Titration
pH 7.8
AEX QyuSpeed D
(FT)
Loading: 4156 mg/mL-BV
MAb: 2.08 mg/ml
Flow rate: 6 BV/min
Aggregate
addition	
Clarification
CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL	
Titration
pH 7.0	
Elution buffer
25mM Acetate; pH 3.4
51
Combination CEX Prototype & AEX QyuSpeed D
CEX prototype
(FT)
52
Combination CEX Prototype & AEX QyuSpeed D
CEX prototype
(FT)
Monomer	 97.6 %	
Dimer / ≧Trimer	 1.79 % / 0.56 %	
HCP	 349 ppm	
Protein A	 3.6 ppm	
Loading to CEX
53
Combination CEX Prototype & AEX QyuSpeed D
CEX prototype
(FT)
Monomer	 97.6 %	
Dimer / ≧Trimer	 1.79 % / 0.56 %	
HCP	 349 ppm	
Protein A	 3.6 ppm	
Loading to CEX	
Flow Through of CEX	
- 88 %
- 20 %
- 83 %
Monomer	 99.66 %	
Dimer / ≧Trimer	 0.28 % / < DL	
HCP	 279 ppm	
Protein A	 0.6 ppm	
Monomer Recovery: 95 %
54
Combination CEX Prototype & AEX QyuSpeed D
CEX prototype
(FT)
Titration
pH 7.8
AEX QyuSpeed D
(FT)
Monomer	 97.6 %	
Dimer / ≧Trimer	 1.79 % / 0.56 %	
HCP	 349 ppm	
Protein A	 3.6 ppm	
Loading to CEX	
Flow Through of CEX	
- 88 %
- 20 %
- 83 %
Monomer	 99.66 %	
Dimer / ≧Trimer	 0.28 % / < DL	
HCP	 279 ppm	
Protein A	 0.6 ppm	
Monomer Recovery: 95 %
55
Combination CEX Prototype & AEX QyuSpeed D
CEX prototype
(FT)
Titration
pH 7.8
AEX QyuSpeed D
(FT)
Monomer	 97.6 %	
Dimer / ≧Trimer	 1.79 % / 0.56 %	
HCP	 349 ppm	
Protein A	 3.6 ppm	
Loading to CEX	
Flow Through of CEX	
Flow Through of AEX	
- 88 %
- 20 %
- 83 %
Monomer	 99.66 %	
Dimer / ≧Trimer	 0.28 % / < DL	
HCP	 279 ppm	
Protein A	 0.6 ppm	
Monomer Recovery: 95 %	
Monomer	 99.75 %	
Dimer / ≧Trimer	 0.18 % / < DL	
HCP	 < 1 ppm	
Protein A	 0.1 ppm	
Monomer Recovery: 99 %	
- 35 %
- 99 %
- 83 %
1) Pathogen Removal Filters
Conclusion
57
Conclusion
ü  Increasing use of membranes in DSP & Flow Through mode preferred
58
Conclusion
ü  Increasing use of membranes in DSP & Flow Through mode preferred
ü  QyuSpeed D for AEX:
•  Unique grafted-chain & hollow fiber design
•  Excellent binding capacity & salt tolerance for DNA, HCP, Virus removal
•  Very flexible implementation: pre or post Protein A, pre or post CEX
•  Single Use or Reusable
59
Conclusion
ü  Increasing use of membranes in DSP & Flow Through mode preferred
ü  QyuSpeed D for AEX:
•  Unique grafted-chain & hollow fiber design
•  Excellent binding capacity & salt tolerance for DNA, HCP, Virus removal
•  Very flexible implementation: pre or post Protein A, pre or post CEX
•  Single Use or Reusable
ü  QyuSpeed Prototype for CEX:
•  Unique grafted-chain & hollow fiber design
•  Flow Through mode
•  High aggregate removal & monomer recovery @ > 1000 g/L loading
•  Single Use or Reusable
60
Conclusion
ü  Increasing use of membranes in DSP & Flow Through mode preferred
ü  QyuSpeed D for AEX:
•  Unique grafted-chain & hollow fiber design
•  Excellent binding capacity & salt tolerance for DNA, HCP, Virus removal
•  Very flexible implementation: pre or post Protein A, pre or post CEX
•  Single Use or Reusable
ü  QyuSpeed Prototype for CEX:
•  Unique grafted-chain & hollow fiber design
•  Flow Through mode
•  High aggregate removal & monomer recovery @ > 1000 g/L loading
•  Single Use or Reusable
ü  Excellent synergy of both QyuSpeed membranes !
61
Thank you to my Japanese colleagues !
Taniguchi-san
Koguma-san
Shirataki-san
Acknowledgements
62
Thank you to my Japanese colleagues !
Taniguchi-san
Koguma-san
Shirataki-san
And my European Colleagues here today !
Mathithas-san and Konstantin-san
Acknowledgements
63
18th Planova Workshop
ü  22nd & 23rd October 2015 in Athens, Greece
ü  Technical presentations by our customers about their experience
with Planova virus removal filters, BioOptimal TFF, QyuSpeed D
ü  Social activities: discover of the ancient city & special
entertainments in the evenings
ü  Number of attendees: 200
ü  YOU ARE WELCOME TO REGISTER !!
ü  www.ak-bio.com/planova-workshop/workshop-2015-athens/description/
64
どうもありがとう	
Domo	Arigato!		
(thank	you	very	much)
65
1.3 m1.4 m
Industrial References
ü  2 customers using already QyuSpeed D modules 5L
§  Impurities removal by AEX (DNA, HCP),
§  Potential enhancement of Prot. A (very expensive step): better
efficiency, easier regeneration, more cycles.
66
Protein A
UFPlanova
AIEX
CIEX
Centri-
fugation
Tangential MF
Depth
Filtration
or
0.2 µm
filtration
AEX with
QyuSpeed D
or much
reduced size
Innovative Implementation: pre Prot. A
Protein A
UFPlanova
AIEX
CIEX
Centri-
fugation
Tangential MF
Depth
Filtration
or
0.2 µm
filtration
67
AEX with
QyuSpeed D
or much
reduced size
Other (very) Innovative Implementation:
cell culture harvesting/clarification
Protein A
UFPlanova
AIEX
CIEX
Centri-
fugation
Tangential MF
Depth
Filtration
or
0.2 µm
filtration
3 actions in 1 single step:
ü  Cell culture clarification (0.2 µm; TFF mode),
ü  AEX chromatography (DNA, Virus & HCP removal),
ü  “Protection” of Protein A.
68
AEX with
QyuSpeed D
or much
reduced size
Other (very) Innovative Implementation:
cell culture harvesting/clarification
69
Aggregate Removal vs. Cond.
70
Feed solution: MAb (h-IgG1), 5 mg/mL, pI 8.4
Buffer: 15 mM Tris-HCl
pH: 7.0
Loading: ~ 1000 mg/mL-membrane volume (BV)
Flow rate: 6 BV/min
Aggregate Removal vs. Cond.
71
Feed solution: MAb (h-IgG1), 5 mg/mL, pI 8.4
Buffer: 15 mM Tris-HCl
pH: 7.0
Loading: ~ 1000 mg/mL-membrane volume (BV)
Flow rate: 6 BV/min
Conductivity (mS/cm)	 1.4 2.6 4.7
Feed
solution	
Monomer (%) 94.73 95.94 95.49
Dimer (%) 2.25 1.59 2.2
≧ Trimer (%) 3.02 2.47 2.31
Aggregate Removal vs. Cond.
72
Aggregate Removal vs. Cond.
1.4 mS/cm 2.6 mS/cm 4.7 mS/cm
73
Conductivity (mS/cm)	 1.4 2.6 4.7
Monomer recovery (%) 88.87 92.32 89.12
Flow Through	
(reduction %)
Monomer (%) 97.42 99.48 98.59
Dimer (%) 1.34 (49) 0.39 (78) 1.03 (60)
≧ Trimer (%) 1.24 (65) 0.13 (95) 0.38 (86)
Aggregate Removal vs. Cond.
1.4 mS/cm 2.6 mS/cm 4.7 mS/cm
pH 7.0
74
Conductivity (mS/cm)	 1.4 2.6 4.7
Monomer recovery (%) 88.87 92.32 89.12
Flow Through	
(reduction %)
Monomer (%) 97.42 99.48 98.59
Dimer (%) 1.34 (49) 0.39 (78) 1.03 (60)
≧ Trimer (%) 1.24 (65) 0.13 (95) 0.38 (86)
Aggregate Removal vs. Cond.
1.4 mS/cm 2.6 mS/cm 4.7 mS/cm
75
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
AEX QyuSpeed D
(FT)
Clarification
CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL
76
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
AEX QyuSpeed D
(FT)
Clarification
CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL	
Elution buffer
0.1M Citrate; pH 3.4
77
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
AEX QyuSpeed D
(FT)
Clarification
CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL	
Buffer change
15 mM Tris-HCl
pH 7.0; Cond. 1.4 mS/cm	
Elution buffer
0.1M Citrate; pH 3.4
78
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
AEX QyuSpeed D
(FT)
Aggregate
addition	
Clarification
CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL	
Buffer change
15 mM Tris-HCl
pH 7.0; Cond. 1.4 mS/cm	
Elution buffer
0.1M Citrate; pH 3.4
79
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
Titration
pH 7.8
AEX QyuSpeed D
(FT)
Aggregate
addition	
Clarification
CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL	
Buffer change
15 mM Tris-HCl
pH 7.0; Cond. 1.4 mS/cm	
Elution buffer
0.1M Citrate; pH 3.4
80
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
Loading: 1067 mg/mL-MV
MAb: 5.22 mg/mL
Flow rate: 6 BV/min
Titration
pH 7.8
AEX QyuSpeed D
(FT)
Aggregate
addition	
Clarification
CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL	
Buffer change
15 mM Tris-HCl
pH 7.0; Cond. 1.4 mS/cm	
Elution buffer
0.1M Citrate; pH 3.4
81
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
Loading: 1067 mg/mL-MV
MAb: 5.22 mg/mL
Flow rate: 6 BV/min
Titration
pH 7.8
AEX QyuSpeed D
(FT)
Loading: 4713 mg/mL-MV
MAb: 3.80 mg/ml
Flow rate: 6 BV/min
Aggregate
addition	
Clarification
CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL	
Buffer change
15 mM Tris-HCl
pH 7.0; Cond. 1.4 mS/cm	
Elution buffer
0.1M Citrate; pH 3.4
82
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
Loading: 1067 mg/mL-MV
MAb: 5.22 mg/mL
Flow rate: 6 BV/min
Titration
pH 7.8
AEX QyuSpeed D
(FT)
Loading: 4713 mg/mL-MV
MAb: 3.80 mg/ml
Flow rate: 6 BV/min
Aggregate
addition	
Clarification
Monomer	 97.77 %	
Dimer /
≧Trimer	
1.32 % / 0.91 %	
HCP	 390 ppm	
Protein A	 0.5 ppm	
Loading to CEX	CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL	
Buffer change
15 mM Tris-HCl
pH 7.0; Cond. 1.4 mS/cm	
Elution buffer
0.1M Citrate; pH 3.4
83
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
Loading: 1067 mg/mL-MV
MAb: 5.22 mg/mL
Flow rate: 6 BV/min
Titration
pH 7.8
AEX QyuSpeed D
(FT)
Loading: 4713 mg/mL-MV
MAb: 3.80 mg/ml
Flow rate: 6 BV/min
Aggregate
addition	
Clarification
Monomer	 97.77 %	
Dimer /
≧Trimer	
1.32 % / 0.91 %	
HCP	 390 ppm	
Protein A	 0.5 ppm	
Loading to CEX	
Flow Through of CEX	
- 79 %
- 35 %
CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL	
- 80 %
Buffer change
15 mM Tris-HCl
pH 7.0; Cond. 1.4 mS/cm	
Monomer	 99.54 %	
Dimer /
≧Trimer	
0.33 % / 0.14 %	
HCP	 254 ppm	
Protein A	 0.1 ppm	
Monomer Recovery: 87 %	
Elution buffer
0.1M Citrate; pH 3.4
84
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
Loading: 1067 mg/mL-MV
MAb: 5.22 mg/mL
Flow rate: 6 BV/min
Titration
pH 7.8
AEX QyuSpeed D
(FT)
Loading: 4713 mg/mL-MV
MAb: 3.80 mg/ml
Flow rate: 6 BV/min
Aggregate
addition	
Clarification
Monomer	 97.77 %	
Dimer /
≧Trimer	
1.32 % / 0.91 %	
HCP	 390 ppm	
Protein A	 0.5 ppm	
Loading to CEX	
Flow Through of CEX	
Flow Through of AEX	
- 79 %
- 35 %
CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL	
- 80 %
Buffer change
15 mM Tris-HCl
pH 7.0; Cond. 1.4 mS/cm	
Monomer	 99.54 %	
Dimer /
≧Trimer	
0.33 % / 0.14 %	
HCP	 254 ppm	
Protein A	 0.1 ppm	
Monomer Recovery: 87 %	
Monomer	 99.79 %	
Dimer /
≧Trimer	
0.21 % / < DL	
HCP	 6 ppm	
Protein A	 < 0.1 ppm	
Monomer Recovery: 99 %	
- 55 %
- 98 %
Elution buffer
0.1M Citrate; pH 3.4
85
Combination CEX Prototype & AEX QyuSpeed D
0	
0.2	
0.4	
0.6	
0.8	
1	
1.2	
0.00		 200.00		 400.00		 600.00		 800.00		1000.00		
C/C0	
Load	IgG(mg/mL-ad)	
CEX	
Monomer	
Dimer	
≧Trimer	
HCP	
protein	A	
0	
0.2	
0.4	
0.6	
0.8	
1	
1.2	
0	 1000	 2000	 3000	 4000	 5000	
C/C0	
Load	IgG(mg/mL-ad)	
AEX	
Monomer	
Dimer	
≧Trimer	
HCP	
Monomer	 97.77 %	
Dimer /
≧Trimer	
1.32 % / 0.91 %	
HCP	 390 ppm	
Protein A	 0.5 ppm	
Loading to CEX	
Flow Through of CEX	
Flow Through of AEX	
- 79 %
- 35 %
- 80 %
Monomer	 99.54 %	
Dimer /
≧Trimer	
0.33 % / 0.14 %	
HCP	 254 ppm	
Protein A	 0.1 ppm	
Monomer Recovery: 87 %	
Monomer	 99.79 %	
Dimer /
≧Trimer	
0.21 % / < DL	
HCP	 6 ppm	
Protein A	 < 0.1 ppm	
Monomer Recovery: 99 %	
- 55 %
- 98 %
86
Combination CEX Prototype & AEX QyuSpeed D
Monomer	 97.6 %	
Dimer /
≧Trimer	
1.79 % / 0.56 %	
HCP	 349 ppm	
Protein A	 3.6 ppm	
Loading to CEX	
Flow Through of CEX	
Flow Through of AEX	
- 88 %
- 20 %
- 83 %
Monomer	 99.66 %	
Dimer /
≧Trimer	
0.28 % / < DL	
HCP	 279 ppm	
Protein A	 0.6 ppm	
Monomer Recovery: 95 %	
Monomer	 99.75 %	
Dimer /
≧Trimer	
0.18 % / < DL	
HCP	 < 1 ppm	
Protein A	 0.1 ppm	
Monomer Recovery: 99 %	
- 35 %
- 99 %
- 83 %
0	
0.2	
0.4	
0.6	
0.8	
1	
1.2	
0	 200	 400	 600	 800	 1000	
C/C0	
Load	IgG(mg/mL-ad)	
CEX	(NCX)	
Monomer	
Dimer	
>Trimer	
HCP	
Protein	A	
0	
0.2	
0.4	
0.6	
0.8	
1	
1.2	
0	 1000	 2000	 3000	 4000	
C/C0	
Load	IgG(mg/mL-ad)	
AEX	(QSD)	
Monomer	
Dimer	
HCP	
Protein	A
87
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
Loading: 1041 mg/mL-MV
MAb: 2.6 mg/mL
Flow rate: 6 BV/min
Titration
pH 7.8
AEX QyuSpeed D
(FT)
Loading: 4156 mg/mL-MV
MAb: 2.08 mg/ml
Flow rate: 6 BV/min
Aggregate
addition	
Clarification
Monomer	 97.6 %	
Dimer /
≧Trimer	
1.79 % / 0.56 %	
HCP	 349 ppm	
Protein A	 3.6 ppm	
Loading to CEX	CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL	
Titration
pH 7.0	
Elution buffer
25mM Acetate; pH 3.4
88
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
Loading: 1041 mg/mL-MV
MAb: 2.6 mg/mL
Flow rate: 6 BV/min
Titration
pH 7.8
AEX QyuSpeed D
(FT)
Loading: 4156 mg/mL-MV
MAb: 2.08 mg/ml
Flow rate: 6 BV/min
Aggregate
addition	
Clarification
Monomer	 97.6 %	
Dimer /
≧Trimer	
1.79 % / 0.56 %	
HCP	 349 ppm	
Protein A	 3.6 ppm	
Loading to CEX	
Flow Through of CEX	
- 88 %
- 20 %
CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL	
- 83 %
Monomer	 99.66 %	
Dimer /
≧Trimer	
0.28 % / < DL	
HCP	 279 ppm	
Protein A	 0.6 ppm	
Monomer Recovery: 95 %	
Titration
pH 7.0	
Elution buffer
25mM Acetate; pH 3.4
89
Combination CEX Prototype & AEX QyuSpeed D
Protein A
(BE)
CEX prototype
(FT)
Loading: 1041 mg/mL-MV
MAb: 2.6 mg/mL
Flow rate: 6 BV/min
Titration
pH 7.8
AEX QyuSpeed D
(FT)
Loading: 4156 mg/mL-MV
MAb: 2.08 mg/ml
Flow rate: 6 BV/min
Aggregate
addition	
Clarification
Monomer	 97.6 %	
Dimer /
≧Trimer	
1.79 % / 0.56 %	
HCP	 349 ppm	
Protein A	 3.6 ppm	
Loading to CEX	
Flow Through of CEX	
Flow Through of AEX	
- 88 %
- 20 %
CHO culture
MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL	
- 83 %
Monomer	 99.66 %	
Dimer /
≧Trimer	
0.28 % / < DL	
HCP	 279 ppm	
Protein A	 0.6 ppm	
Monomer Recovery: 95 %	
Monomer	 99.75 %	
Dimer /
≧Trimer	
0.18 % / < DL	
HCP	 < 1 ppm	
Protein A	 0.1 ppm	
Monomer Recovery: 99 %	
- 35 %
- 99 %
Titration
pH 7.0	
- 83 %
Elution buffer
25mM Acetate; pH 3.4

More Related Content

What's hot

Basic concept of chromatography
Basic concept of chromatographyBasic concept of chromatography
Basic concept of chromatography
PrashantSharma807
 
Chromatography.ppt
Chromatography.pptChromatography.ppt
Chromatography.ppt
ZORAIZ HAIDER
 
non-ideal reactors.pptx
non-ideal reactors.pptxnon-ideal reactors.pptx
non-ideal reactors.pptx
babuskinsrinivasan2
 
Optimization of Tangential Flow Filtration Applications and Scale Up Consider...
Optimization of Tangential Flow Filtration Applications and Scale Up Consider...Optimization of Tangential Flow Filtration Applications and Scale Up Consider...
Optimization of Tangential Flow Filtration Applications and Scale Up Consider...
MilliporeSigma
 
Bio-based solvents
Bio-based solventsBio-based solvents
Bio-based solvents
James Sherwood
 
Mbbr
MbbrMbbr
R e a c t o r s & its kinetics
R e a c t o r s & its kineticsR e a c t o r s & its kinetics
R e a c t o r s & its kinetics
Arvind Kumar
 
Particle Technology- Filtration
Particle Technology- FiltrationParticle Technology- Filtration
Chromatography: Automated solid-phase extraction (SPE) for the Environmental...
Chromatography: Automated  solid-phase extraction (SPE) for the Environmental...Chromatography: Automated  solid-phase extraction (SPE) for the Environmental...
Chromatography: Automated solid-phase extraction (SPE) for the Environmental...
Chromatography & Mass Spectrometry Solutions
 
Hariom ppt report
Hariom ppt reportHariom ppt report
Hariom ppt report
hariom gupta
 
Matlab for Chemical Engineering
Matlab for Chemical EngineeringMatlab for Chemical Engineering
Matlab for Chemical Engineering
Debarun Banerjee
 
Hplc
HplcHplc
Rapid Determination of Inorganic Ions in Wastewater by Ion Chromatography
Rapid Determination of Inorganic Ions in Wastewater by Ion ChromatographyRapid Determination of Inorganic Ions in Wastewater by Ion Chromatography
Rapid Determination of Inorganic Ions in Wastewater by Ion Chromatography
Chromatography & Mass Spectrometry Solutions
 
Introduction to Tangential Flow Filtration (TFF)
Introduction to Tangential Flow Filtration (TFF)Introduction to Tangential Flow Filtration (TFF)
Introduction to Tangential Flow Filtration (TFF)
MilliporeSigma
 
Reactive distillation
Reactive distillationReactive distillation
Reactive distillation
VIVEK GUPTA
 
2 application of moving bed biofilm reactor (mbbr) and integrated fixed activ...
2 application of moving bed biofilm reactor (mbbr) and integrated fixed activ...2 application of moving bed biofilm reactor (mbbr) and integrated fixed activ...
2 application of moving bed biofilm reactor (mbbr) and integrated fixed activ...
Alvaro Huete
 
How to do Column Chromotography
How to do Column ChromotographyHow to do Column Chromotography
How to do Column Chromotography
Cognibrain Healthcare
 
An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...
An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...
An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...
Merck Life Sciences
 
Floating islands
Floating islandsFloating islands
Floating islands
GCUF
 
Millipak® Final Fill Filters
Millipak® Final Fill FiltersMillipak® Final Fill Filters
Millipak® Final Fill Filters
MilliporeSigma
 

What's hot (20)

Basic concept of chromatography
Basic concept of chromatographyBasic concept of chromatography
Basic concept of chromatography
 
Chromatography.ppt
Chromatography.pptChromatography.ppt
Chromatography.ppt
 
non-ideal reactors.pptx
non-ideal reactors.pptxnon-ideal reactors.pptx
non-ideal reactors.pptx
 
Optimization of Tangential Flow Filtration Applications and Scale Up Consider...
Optimization of Tangential Flow Filtration Applications and Scale Up Consider...Optimization of Tangential Flow Filtration Applications and Scale Up Consider...
Optimization of Tangential Flow Filtration Applications and Scale Up Consider...
 
Bio-based solvents
Bio-based solventsBio-based solvents
Bio-based solvents
 
Mbbr
MbbrMbbr
Mbbr
 
R e a c t o r s & its kinetics
R e a c t o r s & its kineticsR e a c t o r s & its kinetics
R e a c t o r s & its kinetics
 
Particle Technology- Filtration
Particle Technology- FiltrationParticle Technology- Filtration
Particle Technology- Filtration
 
Chromatography: Automated solid-phase extraction (SPE) for the Environmental...
Chromatography: Automated  solid-phase extraction (SPE) for the Environmental...Chromatography: Automated  solid-phase extraction (SPE) for the Environmental...
Chromatography: Automated solid-phase extraction (SPE) for the Environmental...
 
Hariom ppt report
Hariom ppt reportHariom ppt report
Hariom ppt report
 
Matlab for Chemical Engineering
Matlab for Chemical EngineeringMatlab for Chemical Engineering
Matlab for Chemical Engineering
 
Hplc
HplcHplc
Hplc
 
Rapid Determination of Inorganic Ions in Wastewater by Ion Chromatography
Rapid Determination of Inorganic Ions in Wastewater by Ion ChromatographyRapid Determination of Inorganic Ions in Wastewater by Ion Chromatography
Rapid Determination of Inorganic Ions in Wastewater by Ion Chromatography
 
Introduction to Tangential Flow Filtration (TFF)
Introduction to Tangential Flow Filtration (TFF)Introduction to Tangential Flow Filtration (TFF)
Introduction to Tangential Flow Filtration (TFF)
 
Reactive distillation
Reactive distillationReactive distillation
Reactive distillation
 
2 application of moving bed biofilm reactor (mbbr) and integrated fixed activ...
2 application of moving bed biofilm reactor (mbbr) and integrated fixed activ...2 application of moving bed biofilm reactor (mbbr) and integrated fixed activ...
2 application of moving bed biofilm reactor (mbbr) and integrated fixed activ...
 
How to do Column Chromotography
How to do Column ChromotographyHow to do Column Chromotography
How to do Column Chromotography
 
An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...
An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...
An Efficient and cGMP-friendly Solution to Diafiltration for Intensified or C...
 
Floating islands
Floating islandsFloating islands
Floating islands
 
Millipak® Final Fill Filters
Millipak® Final Fill FiltersMillipak® Final Fill Filters
Millipak® Final Fill Filters
 

Similar to New Hollow Fiber Membranes for AEX and CEX in Flow-Through Mode

Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
MilliporeSigma
 
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Merck Life Sciences
 
BILS 2015 Tosoh Bioscience
BILS 2015 Tosoh BioscienceBILS 2015 Tosoh Bioscience
BILS 2015 Tosoh Bioscience
GBX Events
 
Monoclonal antibodies,Production + bioseperartion
Monoclonal antibodies,Production + bioseperartionMonoclonal antibodies,Production + bioseperartion
Monoclonal antibodies,Production + bioseperartion
shadan87
 
Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...
Merck Life Sciences
 
Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...
MilliporeSigma
 
TOYOPEARL MX-Trp-650M
TOYOPEARL MX-Trp-650MTOYOPEARL MX-Trp-650M
TOYOPEARL MX-Trp-650M
Romain Dabre
 
Multi-residue pesticide analysis of food samples using acetonitrile extractio...
Multi-residue pesticide analysis of food samples using acetonitrile extractio...Multi-residue pesticide analysis of food samples using acetonitrile extractio...
Multi-residue pesticide analysis of food samples using acetonitrile extractio...Kate?ina Svobodov
 
Spps and its applications for bioactive peptides(Rajendra Sonawane)
Spps and its applications for bioactive peptides(Rajendra Sonawane)Spps and its applications for bioactive peptides(Rajendra Sonawane)
Spps and its applications for bioactive peptides(Rajendra Sonawane)
Rajendra Sonawane
 
Dicam post-trattamento_case study
Dicam post-trattamento_case studyDicam post-trattamento_case study
Dicam post-trattamento_case study
SYNECO
 
Measuring pKas, logP and Solubility by Automated titration
Measuring pKas, logP and Solubility by Automated titrationMeasuring pKas, logP and Solubility by Automated titration
Measuring pKas, logP and Solubility by Automated titration
Jon Mole
 
BioInnovation Leader Summit Transforming Process Efficiency
 BioInnovation Leader Summit Transforming Process Efficiency BioInnovation Leader Summit Transforming Process Efficiency
BioInnovation Leader Summit Transforming Process Efficiency
GBX Summits
 
Dr. Elke Prohaska & Regina Römling BioInnovation Leader Summit Tosoh
Dr. Elke Prohaska & Regina Römling BioInnovation Leader Summit TosohDr. Elke Prohaska & Regina Römling BioInnovation Leader Summit Tosoh
Dr. Elke Prohaska & Regina Römling BioInnovation Leader Summit Tosoh
GBX Summits
 
Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...
Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...
Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...
PerkinElmer, Inc.
 
New Ultra-High Capacity TOYOPEARL® Protein A Resin
New Ultra-High Capacity TOYOPEARL® Protein A Resin New Ultra-High Capacity TOYOPEARL® Protein A Resin
New Ultra-High Capacity TOYOPEARL® Protein A Resin
Tosoh Bioscience GmbH
 
Pds pure blueh2o- pb-tlro4h50t - performance data sheet - 2-27-2015
Pds   pure blueh2o- pb-tlro4h50t - performance data sheet - 2-27-2015Pds   pure blueh2o- pb-tlro4h50t - performance data sheet - 2-27-2015
Pds pure blueh2o- pb-tlro4h50t - performance data sheet - 2-27-2015
Cindy Wilton-Maisner
 
GRC_Poster_2015
GRC_Poster_2015GRC_Poster_2015
GRC_Poster_2015David Gunn
 
Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up	Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up
MilliporeSigma
 
Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-upComplete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up
Merck Life Sciences
 
Chromatography: Trends and Developments in MAb Screening and Characterization
Chromatography: Trends and Developments in MAb Screening and CharacterizationChromatography: Trends and Developments in MAb Screening and Characterization
Chromatography: Trends and Developments in MAb Screening and Characterization
Chromatography & Mass Spectrometry Solutions
 

Similar to New Hollow Fiber Membranes for AEX and CEX in Flow-Through Mode (20)

Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
 
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Plat...
 
BILS 2015 Tosoh Bioscience
BILS 2015 Tosoh BioscienceBILS 2015 Tosoh Bioscience
BILS 2015 Tosoh Bioscience
 
Monoclonal antibodies,Production + bioseperartion
Monoclonal antibodies,Production + bioseperartionMonoclonal antibodies,Production + bioseperartion
Monoclonal antibodies,Production + bioseperartion
 
Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...
 
Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...Process Development for Continuous Flow-Through Polishing Purification for mA...
Process Development for Continuous Flow-Through Polishing Purification for mA...
 
TOYOPEARL MX-Trp-650M
TOYOPEARL MX-Trp-650MTOYOPEARL MX-Trp-650M
TOYOPEARL MX-Trp-650M
 
Multi-residue pesticide analysis of food samples using acetonitrile extractio...
Multi-residue pesticide analysis of food samples using acetonitrile extractio...Multi-residue pesticide analysis of food samples using acetonitrile extractio...
Multi-residue pesticide analysis of food samples using acetonitrile extractio...
 
Spps and its applications for bioactive peptides(Rajendra Sonawane)
Spps and its applications for bioactive peptides(Rajendra Sonawane)Spps and its applications for bioactive peptides(Rajendra Sonawane)
Spps and its applications for bioactive peptides(Rajendra Sonawane)
 
Dicam post-trattamento_case study
Dicam post-trattamento_case studyDicam post-trattamento_case study
Dicam post-trattamento_case study
 
Measuring pKas, logP and Solubility by Automated titration
Measuring pKas, logP and Solubility by Automated titrationMeasuring pKas, logP and Solubility by Automated titration
Measuring pKas, logP and Solubility by Automated titration
 
BioInnovation Leader Summit Transforming Process Efficiency
 BioInnovation Leader Summit Transforming Process Efficiency BioInnovation Leader Summit Transforming Process Efficiency
BioInnovation Leader Summit Transforming Process Efficiency
 
Dr. Elke Prohaska & Regina Römling BioInnovation Leader Summit Tosoh
Dr. Elke Prohaska & Regina Römling BioInnovation Leader Summit TosohDr. Elke Prohaska & Regina Römling BioInnovation Leader Summit Tosoh
Dr. Elke Prohaska & Regina Römling BioInnovation Leader Summit Tosoh
 
Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...
Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...
Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...
 
New Ultra-High Capacity TOYOPEARL® Protein A Resin
New Ultra-High Capacity TOYOPEARL® Protein A Resin New Ultra-High Capacity TOYOPEARL® Protein A Resin
New Ultra-High Capacity TOYOPEARL® Protein A Resin
 
Pds pure blueh2o- pb-tlro4h50t - performance data sheet - 2-27-2015
Pds   pure blueh2o- pb-tlro4h50t - performance data sheet - 2-27-2015Pds   pure blueh2o- pb-tlro4h50t - performance data sheet - 2-27-2015
Pds pure blueh2o- pb-tlro4h50t - performance data sheet - 2-27-2015
 
GRC_Poster_2015
GRC_Poster_2015GRC_Poster_2015
GRC_Poster_2015
 
Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up	Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up
 
Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-upComplete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up
 
Chromatography: Trends and Developments in MAb Screening and Characterization
Chromatography: Trends and Developments in MAb Screening and CharacterizationChromatography: Trends and Developments in MAb Screening and Characterization
Chromatography: Trends and Developments in MAb Screening and Characterization
 

More from GBX Events

BILS 2015 University of Birmingham Roy Jefferis
BILS 2015 University of Birmingham Roy JefferisBILS 2015 University of Birmingham Roy Jefferis
BILS 2015 University of Birmingham Roy Jefferis
GBX Events
 
BILS 2015 Umetrics Stefan Raennar
BILS 2015 Umetrics Stefan RaennarBILS 2015 Umetrics Stefan Raennar
BILS 2015 Umetrics Stefan Raennar
GBX Events
 
BILS 2015 Bayer Pharma AG Markus Eser
BILS 2015 Bayer Pharma AG Markus EserBILS 2015 Bayer Pharma AG Markus Eser
BILS 2015 Bayer Pharma AG Markus Eser
GBX Events
 
BILS 2015 Christoph Herwig
BILS 2015 Christoph HerwigBILS 2015 Christoph Herwig
BILS 2015 Christoph Herwig
GBX Events
 
BILS 2015 Genethon M. Hebben
BILS 2015 Genethon M. HebbenBILS 2015 Genethon M. Hebben
BILS 2015 Genethon M. Hebben
GBX Events
 
BILS 2015 OctoPlus and Dr. Reddy's
BILS 2015 OctoPlus and Dr. Reddy'sBILS 2015 OctoPlus and Dr. Reddy's
BILS 2015 OctoPlus and Dr. Reddy's
GBX Events
 
BILS 2015, F. Wolpers Hamilton Bonaduz AG
BILS 2015, F. Wolpers Hamilton Bonaduz AGBILS 2015, F. Wolpers Hamilton Bonaduz AG
BILS 2015, F. Wolpers Hamilton Bonaduz AG
GBX Events
 
Ingenza BILS 2016
Ingenza BILS 2016Ingenza BILS 2016
Ingenza BILS 2016
GBX Events
 
Novartis BILS 2016
Novartis BILS 2016Novartis BILS 2016
Novartis BILS 2016
GBX Events
 
Newcastle BILS 2016
Newcastle BILS 2016Newcastle BILS 2016
Newcastle BILS 2016
GBX Events
 
Filtrox BILS 2016
Filtrox BILS 2016Filtrox BILS 2016
Filtrox BILS 2016
GBX Events
 
Soligenix BILS 2016
Soligenix BILS 2016Soligenix BILS 2016
Soligenix BILS 2016
GBX Events
 
BOKU BILS 2016
BOKU BILS 2016BOKU BILS 2016
BOKU BILS 2016
GBX Events
 
Boedeker Bayer BILS 2016
Boedeker Bayer BILS 2016Boedeker Bayer BILS 2016
Boedeker Bayer BILS 2016
GBX Events
 
Tosoh BILS 2016
Tosoh BILS 2016Tosoh BILS 2016
Tosoh BILS 2016
GBX Events
 
Contemporary Clinical Trials 2015
Contemporary Clinical Trials 2015Contemporary Clinical Trials 2015
Contemporary Clinical Trials 2015
GBX Events
 
DEC 3 2015 Mats Sundgren
DEC 3 2015 Mats SundgrenDEC 3 2015 Mats Sundgren
DEC 3 2015 Mats Sundgren
GBX Events
 
Press release
Press releasePress release
Press release
GBX Events
 
PIMS Feb. 2016 DHL Resilience360
PIMS Feb. 2016 DHL Resilience360PIMS Feb. 2016 DHL Resilience360
PIMS Feb. 2016 DHL Resilience360
GBX Events
 
PIMS Feb. 2016 Packaging Innovation
PIMS Feb. 2016 Packaging Innovation PIMS Feb. 2016 Packaging Innovation
PIMS Feb. 2016 Packaging Innovation
GBX Events
 

More from GBX Events (20)

BILS 2015 University of Birmingham Roy Jefferis
BILS 2015 University of Birmingham Roy JefferisBILS 2015 University of Birmingham Roy Jefferis
BILS 2015 University of Birmingham Roy Jefferis
 
BILS 2015 Umetrics Stefan Raennar
BILS 2015 Umetrics Stefan RaennarBILS 2015 Umetrics Stefan Raennar
BILS 2015 Umetrics Stefan Raennar
 
BILS 2015 Bayer Pharma AG Markus Eser
BILS 2015 Bayer Pharma AG Markus EserBILS 2015 Bayer Pharma AG Markus Eser
BILS 2015 Bayer Pharma AG Markus Eser
 
BILS 2015 Christoph Herwig
BILS 2015 Christoph HerwigBILS 2015 Christoph Herwig
BILS 2015 Christoph Herwig
 
BILS 2015 Genethon M. Hebben
BILS 2015 Genethon M. HebbenBILS 2015 Genethon M. Hebben
BILS 2015 Genethon M. Hebben
 
BILS 2015 OctoPlus and Dr. Reddy's
BILS 2015 OctoPlus and Dr. Reddy'sBILS 2015 OctoPlus and Dr. Reddy's
BILS 2015 OctoPlus and Dr. Reddy's
 
BILS 2015, F. Wolpers Hamilton Bonaduz AG
BILS 2015, F. Wolpers Hamilton Bonaduz AGBILS 2015, F. Wolpers Hamilton Bonaduz AG
BILS 2015, F. Wolpers Hamilton Bonaduz AG
 
Ingenza BILS 2016
Ingenza BILS 2016Ingenza BILS 2016
Ingenza BILS 2016
 
Novartis BILS 2016
Novartis BILS 2016Novartis BILS 2016
Novartis BILS 2016
 
Newcastle BILS 2016
Newcastle BILS 2016Newcastle BILS 2016
Newcastle BILS 2016
 
Filtrox BILS 2016
Filtrox BILS 2016Filtrox BILS 2016
Filtrox BILS 2016
 
Soligenix BILS 2016
Soligenix BILS 2016Soligenix BILS 2016
Soligenix BILS 2016
 
BOKU BILS 2016
BOKU BILS 2016BOKU BILS 2016
BOKU BILS 2016
 
Boedeker Bayer BILS 2016
Boedeker Bayer BILS 2016Boedeker Bayer BILS 2016
Boedeker Bayer BILS 2016
 
Tosoh BILS 2016
Tosoh BILS 2016Tosoh BILS 2016
Tosoh BILS 2016
 
Contemporary Clinical Trials 2015
Contemporary Clinical Trials 2015Contemporary Clinical Trials 2015
Contemporary Clinical Trials 2015
 
DEC 3 2015 Mats Sundgren
DEC 3 2015 Mats SundgrenDEC 3 2015 Mats Sundgren
DEC 3 2015 Mats Sundgren
 
Press release
Press releasePress release
Press release
 
PIMS Feb. 2016 DHL Resilience360
PIMS Feb. 2016 DHL Resilience360PIMS Feb. 2016 DHL Resilience360
PIMS Feb. 2016 DHL Resilience360
 
PIMS Feb. 2016 Packaging Innovation
PIMS Feb. 2016 Packaging Innovation PIMS Feb. 2016 Packaging Innovation
PIMS Feb. 2016 Packaging Innovation
 

Recently uploaded

Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...
University of Maribor
 
Eukaryotic Transcription Presentation.pptx
Eukaryotic Transcription Presentation.pptxEukaryotic Transcription Presentation.pptx
Eukaryotic Transcription Presentation.pptx
RitabrataSarkar3
 
ANAMOLOUS SECONDARY GROWTH IN DICOT ROOTS.pptx
ANAMOLOUS SECONDARY GROWTH IN DICOT ROOTS.pptxANAMOLOUS SECONDARY GROWTH IN DICOT ROOTS.pptx
ANAMOLOUS SECONDARY GROWTH IN DICOT ROOTS.pptx
RASHMI M G
 
Richard's aventures in two entangled wonderlands
Richard's aventures in two entangled wonderlandsRichard's aventures in two entangled wonderlands
Richard's aventures in two entangled wonderlands
Richard Gill
 
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...
THEMATIC  APPERCEPTION  TEST(TAT) cognitive abilities, creativity, and critic...THEMATIC  APPERCEPTION  TEST(TAT) cognitive abilities, creativity, and critic...
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...
Abdul Wali Khan University Mardan,kP,Pakistan
 
Anemia_ types_clinical significance.pptx
Anemia_ types_clinical significance.pptxAnemia_ types_clinical significance.pptx
Anemia_ types_clinical significance.pptx
muralinath2
 
Red blood cells- genesis-maturation.pptx
Red blood cells- genesis-maturation.pptxRed blood cells- genesis-maturation.pptx
Red blood cells- genesis-maturation.pptx
muralinath2
 
ESR spectroscopy in liquid food and beverages.pptx
ESR spectroscopy in liquid food and beverages.pptxESR spectroscopy in liquid food and beverages.pptx
ESR spectroscopy in liquid food and beverages.pptx
PRIYANKA PATEL
 
Shallowest Oil Discovery of Turkiye.pptx
Shallowest Oil Discovery of Turkiye.pptxShallowest Oil Discovery of Turkiye.pptx
Shallowest Oil Discovery of Turkiye.pptx
Gokturk Mehmet Dilci
 
原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样
原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样
原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样
yqqaatn0
 
Nucleophilic Addition of carbonyl compounds.pptx
Nucleophilic Addition of carbonyl  compounds.pptxNucleophilic Addition of carbonyl  compounds.pptx
Nucleophilic Addition of carbonyl compounds.pptx
SSR02
 
Chapter 12 - climate change and the energy crisis
Chapter 12 - climate change and the energy crisisChapter 12 - climate change and the energy crisis
Chapter 12 - climate change and the energy crisis
tonzsalvador2222
 
Orion Air Quality Monitoring Systems - CWS
Orion Air Quality Monitoring Systems - CWSOrion Air Quality Monitoring Systems - CWS
Orion Air Quality Monitoring Systems - CWS
Columbia Weather Systems
 
Lateral Ventricles.pdf very easy good diagrams comprehensive
Lateral Ventricles.pdf very easy good diagrams comprehensiveLateral Ventricles.pdf very easy good diagrams comprehensive
Lateral Ventricles.pdf very easy good diagrams comprehensive
silvermistyshot
 
Topic: SICKLE CELL DISEASE IN CHILDREN-3.pdf
Topic: SICKLE CELL DISEASE IN CHILDREN-3.pdfTopic: SICKLE CELL DISEASE IN CHILDREN-3.pdf
Topic: SICKLE CELL DISEASE IN CHILDREN-3.pdf
TinyAnderson
 
DMARDs Pharmacolgy Pharm D 5th Semester.pdf
DMARDs Pharmacolgy Pharm D 5th Semester.pdfDMARDs Pharmacolgy Pharm D 5th Semester.pdf
DMARDs Pharmacolgy Pharm D 5th Semester.pdf
fafyfskhan251kmf
 
Nutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technologyNutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technology
Lokesh Patil
 
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốtmô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
HongcNguyn6
 
bordetella pertussis.................................ppt
bordetella pertussis.................................pptbordetella pertussis.................................ppt
bordetella pertussis.................................ppt
kejapriya1
 
What is greenhouse gasses and how many gasses are there to affect the Earth.
What is greenhouse gasses and how many gasses are there to affect the Earth.What is greenhouse gasses and how many gasses are there to affect the Earth.
What is greenhouse gasses and how many gasses are there to affect the Earth.
moosaasad1975
 

Recently uploaded (20)

Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...
Remote Sensing and Computational, Evolutionary, Supercomputing, and Intellige...
 
Eukaryotic Transcription Presentation.pptx
Eukaryotic Transcription Presentation.pptxEukaryotic Transcription Presentation.pptx
Eukaryotic Transcription Presentation.pptx
 
ANAMOLOUS SECONDARY GROWTH IN DICOT ROOTS.pptx
ANAMOLOUS SECONDARY GROWTH IN DICOT ROOTS.pptxANAMOLOUS SECONDARY GROWTH IN DICOT ROOTS.pptx
ANAMOLOUS SECONDARY GROWTH IN DICOT ROOTS.pptx
 
Richard's aventures in two entangled wonderlands
Richard's aventures in two entangled wonderlandsRichard's aventures in two entangled wonderlands
Richard's aventures in two entangled wonderlands
 
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...
THEMATIC  APPERCEPTION  TEST(TAT) cognitive abilities, creativity, and critic...THEMATIC  APPERCEPTION  TEST(TAT) cognitive abilities, creativity, and critic...
THEMATIC APPERCEPTION TEST(TAT) cognitive abilities, creativity, and critic...
 
Anemia_ types_clinical significance.pptx
Anemia_ types_clinical significance.pptxAnemia_ types_clinical significance.pptx
Anemia_ types_clinical significance.pptx
 
Red blood cells- genesis-maturation.pptx
Red blood cells- genesis-maturation.pptxRed blood cells- genesis-maturation.pptx
Red blood cells- genesis-maturation.pptx
 
ESR spectroscopy in liquid food and beverages.pptx
ESR spectroscopy in liquid food and beverages.pptxESR spectroscopy in liquid food and beverages.pptx
ESR spectroscopy in liquid food and beverages.pptx
 
Shallowest Oil Discovery of Turkiye.pptx
Shallowest Oil Discovery of Turkiye.pptxShallowest Oil Discovery of Turkiye.pptx
Shallowest Oil Discovery of Turkiye.pptx
 
原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样
原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样
原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样
 
Nucleophilic Addition of carbonyl compounds.pptx
Nucleophilic Addition of carbonyl  compounds.pptxNucleophilic Addition of carbonyl  compounds.pptx
Nucleophilic Addition of carbonyl compounds.pptx
 
Chapter 12 - climate change and the energy crisis
Chapter 12 - climate change and the energy crisisChapter 12 - climate change and the energy crisis
Chapter 12 - climate change and the energy crisis
 
Orion Air Quality Monitoring Systems - CWS
Orion Air Quality Monitoring Systems - CWSOrion Air Quality Monitoring Systems - CWS
Orion Air Quality Monitoring Systems - CWS
 
Lateral Ventricles.pdf very easy good diagrams comprehensive
Lateral Ventricles.pdf very easy good diagrams comprehensiveLateral Ventricles.pdf very easy good diagrams comprehensive
Lateral Ventricles.pdf very easy good diagrams comprehensive
 
Topic: SICKLE CELL DISEASE IN CHILDREN-3.pdf
Topic: SICKLE CELL DISEASE IN CHILDREN-3.pdfTopic: SICKLE CELL DISEASE IN CHILDREN-3.pdf
Topic: SICKLE CELL DISEASE IN CHILDREN-3.pdf
 
DMARDs Pharmacolgy Pharm D 5th Semester.pdf
DMARDs Pharmacolgy Pharm D 5th Semester.pdfDMARDs Pharmacolgy Pharm D 5th Semester.pdf
DMARDs Pharmacolgy Pharm D 5th Semester.pdf
 
Nutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technologyNutraceutical market, scope and growth: Herbal drug technology
Nutraceutical market, scope and growth: Herbal drug technology
 
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốtmô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
 
bordetella pertussis.................................ppt
bordetella pertussis.................................pptbordetella pertussis.................................ppt
bordetella pertussis.................................ppt
 
What is greenhouse gasses and how many gasses are there to affect the Earth.
What is greenhouse gasses and how many gasses are there to affect the Earth.What is greenhouse gasses and how many gasses are there to affect the Earth.
What is greenhouse gasses and how many gasses are there to affect the Earth.
 

New Hollow Fiber Membranes for AEX and CEX in Flow-Through Mode

  • 1. New Hollow Fiber Membranes for AEX and CEX in Flow-Through Mode Bixente MARTIRENE, MSc Senior Product Manager Asahi Kasei Bioprocess Europe b.martirene@akbio.eu 8th Annual European BioInnovation Leaders Summit 10th - 11th February 2015 Radisson Blu Edwardian Hotel, London www.ak-bio.com
  • 2. 1) Pathogen Removal Filters Content Introduction 1)  Hollow Fiber Membrane for AEX: QyuSpeed D 2)  Hollow Fiber Membrane Prototype for CEX 3)  Case study: Combination of CEX Prototype & AEX QyuSpeed D Conclusion
  • 3. Foundation: 1931; HQ: Tokyo; Employees: 25 000; Turnover: 16 B$ Asahi Kasei Group 3
  • 5. PlanovaTM Virus removal filters QyuSpeedTM D AEX adsorber BioOptimalTM MF-SL TFF microfilter Asahi Kasei Bioprocess 5
  • 6. PlanovaTM Virus removal filters QyuSpeedTM D AEX adsorber BioOptimalTM MF-SL TFF microfilter Systems & Equipment Asahi Kasei Bioprocess 6
  • 7. PlanovaTM Virus removal filters QyuSpeedTM D AEX adsorber BioOptimalTM MF-SL TFF microfilter Systems & Equipment CellufineTM Cellulose Beads Chromatography media (made by JMC Corporation) Asahi Kasei Bioprocess 7
  • 8. 1) Pathogen Removal Filters Introduction
  • 9. 9 Why Membrane vs. Resin ? ü  Mass transfer: “fast” convection vs. “slow” diffusion ü  5-13 BV*/min vs. 0.5-2 BV/min, low pressure drop ü  10-20 x higher loading capacity ➔ smaller BV required ü  Easy setup & operation ≈ Dead-End Filter Introduction * : Bed Volume = Column Volume = Membrane Volume
  • 10. 10 Introduction Feedback from our customers: ü  Flow-Through mode preferred for ease of use ü  AEX adsorbers more & more implemented in DSP ü  CEX mainly performed with classical resins
  • 11. 11 Introduction Asahi Kasei BioProcess: ü  QyuSpeed D launched in 2011 for AEX ➔ Success ü  New Hollow Fiber Membrane for CEX in FT mode ???
  • 12. 1) Pathogen Removal Filters 1)  Hollow Fiber Membrane for AEX: QyuSpeed D
  • 13. 13 QyuSpeed D AEX Adsorber Inlet Outlet QyuSpeed D Module
  • 14. 14 QyuSpeed D AEX Adsorber Inlet Outlet Hollow fiberQyuSpeed D Module Protein solution with biomolecules - Protein solution biomolecules - free §  Dead-End filtration §  Removal of HCP, DNA, Virus
  • 15. 15 QyuSpeed D AEX Adsorber Inside the pore Grafted chain with DEA ligands Biomolecules - Micropore 0.2-0.3 µm >
  • 16. 16 QyuSpeed D AEX Adsorber Inside the pore Grafted chain with DEA ligands Biomolecules - Micropore 0.2-0.3 µm H2C C-C-O-CH2CHCH2H3C- = O HO NH(CH2CH3)2 + () H2C C-C-O-CH2CHCH2H3C- = O HO () NH(CH2CH3)2 + Poly glycidyl methacrylate Grafted chain DEA > >
  • 17. 17 QyuSpeed D AEX Adsorber ü  Multipoint adsorption ü  High ligand density Inside the pore Grafted chain with DEA ligands Biomolecules - Micropore 0.2-0.3 µm H2C C-C-O-CH2CHCH2H3C- = O HO NH(CH2CH3)2 + () H2C C-C-O-CH2CHCH2H3C- = O HO () NH(CH2CH3)2 + Poly glycidyl methacrylate Grafted chain DEA ➔ high DBC & Salt tolerance > >
  • 18. 18 Product Line-Up Membrane (Bed) Volume 0.6 mL 150 mL 550 mL 5 L Maximum Flow Rate 8 mL/min 2 L/min 8 L/min 60 L/min 0.6 mL 150 mL 550 mL 5 L 1172 mm 315 mm
  • 20. 1)  Post Protein A, in place of traditional AEX resin column 2)  Post CEX w/o any prior dilution or buffer change: salt tolerant Protein A UFPlanova CIEX Centri- fugation Tangential MF Depth Filtration or 0.2 µm filtration 20 AEX with QyuSpeed D Classical Implementations of QyuSpeed D
  • 21. 10% BSA DBC > 40 g/L-BV 10% DNA DBC @ 15 mS/cm < 30 g/L-BV HCP reduction 25 – 99 % removal (depending on pI of HCP) Parvovirus LRV > 4 Log MAb Loading capacity Post Protein A (in standard flow through mode) > 2000 g/L-BV (depending on quantities of impurities) Number of regenerations > 10 (tested up to 100 x with BSA) 21 Performances
  • 22. 22 Advantages vs. other AEX Adsorbers ü  Same membrane for low or high conductivity solutions ü  “flexible” implementation: pre or post Prot. A, pre or post CEX ü  Single-use or Reusable (1M NaCl; 1N NaOH)
  • 23. 23 2)  Hollow Fiber Membrane Prototype for CEX
  • 24. 24 2)  Hollow Fiber Membrane Prototype for CEX ➔ CEX in FT mode
  • 25. 25 New QyuSpeed Prototype for CEX Inlet Lab module Outlet
  • 26. 26 New QyuSpeed Prototype for CEX Inlet §  Flow Through mode = Dead- End filtration §  Removal of Aggregates, Prot. A, HCP Outlet Lab module
  • 27. 27 New QyuSpeed Prototype for CEX Inlet Hollow fiber Protein solution with aggregates Protein solution aggregate free Outlet Lab module §  Flow Through mode = Dead- End filtration §  Removal of Aggregates, Prot. A, HCP
  • 28. 28 Inside the pore Grafted chain with 3 different ligands Aggregate Micropore 0.2-0.3 µm > New QyuSpeed Prototype for CEX
  • 29. 29 Inside the pore Grafted chain with 3 different ligands Aggregate Micropore 0.2-0.3 µm Grafted chain > > New QyuSpeed Prototype for CEX -R1 -R2 -R3 R1, R2 & R3 are side chains with different ligands & interactions
  • 31. 31 Aggregate Removal vs. pH Feed solution: MAb (h-IgG1), 5 mg/mL, pI 8.4 Buffer: 15 mM Tris-HCl Conductivity: 1.4 mS/cm Loading: ~ 1 000 g/L-membrane volume (BV) Flow rate: 6 BV/min Aggregate content: ~ 5 %
  • 32. 32 Aggregate Removal vs. pH Feed solution: MAb (h-IgG1), 5 mg/mL, pI 8.4 Buffer: 15 mM Tris-HCl Conductivity: 1.4 mS/cm Loading: ~ 1 000 g/L-membrane volume (BV) Flow rate: 6 BV/min Aggregate content: ~ 5 % pH 7.0 pH 7.5 pH 8.0 Feed solution Monomer (%) 94.73 94.51 93.54 Dimer (%) 2.25 2.76 3.58 ≧ Trimer (%) 3.02 2.73 2.88
  • 33. 33 Aggregate Removal vs. pH pH 7.0 pH 7.5 pH 8.0
  • 34. 34 Aggregate Removal vs. pH pH 7.0 pH 7.5 pH 8.0 pH 7.0 pH 7.5 pH 8.0 Monomer recovery (%) 88.87 92.2 93.07
  • 35. 35 Aggregate Removal vs. pH pH 7.0 pH 7.5 pH 8.0 pH 7.0 pH 7.5 pH 8.0 Monomer recovery (%) 88.87 92.2 93.07 Flow Through (reduction %) Monomer (%) 97.42 Dimer (%) 1.34 (49) ≧ Trimer (%) 1.24 (65)
  • 36. 36 Aggregate Removal vs. pH pH 7.0 pH 7.5 pH 8.0 pH 7.0 pH 7.5 pH 8.0 Monomer recovery (%) 88.87 92.2 93.07 Flow Through (reduction %) Monomer (%) 97.42 98.65 Dimer (%) 1.34 (49) 1.10 (65) ≧ Trimer (%) 1.24 (65) 0.25 (92)
  • 37. 37 Aggregate Removal vs. pH pH 7.0 pH 7.5 pH 8.0 pH 7.0 pH 7.5 pH 8.0 Monomer recovery (%) 88.87 92.2 93.07 Flow Through (reduction %) Monomer (%) 97.42 98.65 97.98 Dimer (%) 1.34 (49) 1.10 (65) 1.74 (57) ≧ Trimer (%) 1.24 (65) 0.25 (92) 0.28 (91)
  • 38. 38 Aggregate Removal vs. pH pH 7.0 pH 7.5 pH 8.0 pH 7.0 pH 7.5 pH 8.0 Monomer recovery (%) 88.87 92.2 93.07 Flow Through (reduction %) Monomer (%) 97.42 98.65 97.98 Dimer (%) 1.34 (49) 1.10 (65) 1.74 (57) ≧ Trimer (%) 1.24 (65) 0.25 (92) 0.28 (91)
  • 40. 40 Aggregate Removal vs. Cond. 1.4 mS/cm 2.6 mS/cm 4.7 mS/cm
  • 41. 41 Conductivity (mS/cm) 1.4 2.6 4.7 Monomer recovery (%) 88.87 92.32 89.12 Flow Through (reduction %) Monomer (%) 97.42 99.48 98.59 Dimer (%) 1.34 (49) 0.39 (78) 1.03 (60) ≧ Trimer (%) 1.24 (65) 0.13 (95) 0.38 (86) Aggregate Removal vs. Cond. 1.4 mS/cm 2.6 mS/cm 4.7 mS/cm pH 7.0
  • 42. 42 Comments on the Performances ü  Performances linked to pH & Cond. ➔ optimizations ü  ~ 90 % monomer recovery (binding at the beginning) ü  Up to 95 % aggregate removal possible ü  > 1 000 g/L-BV loading capacity ➔ 10-20 x higher loading capacity vs. traditional CEX resin
  • 43. 1) Pathogen Removal Filters 3)  Case study: Combination of CEX Prototype & AEX QyuSpeed D
  • 44. 44 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) AEX QyuSpeed D (FT) Clarification CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL
  • 45. 45 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) AEX QyuSpeed D (FT) Clarification CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL Elution buffer 25mM Acetate; pH 3.4
  • 46. 46 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) AEX QyuSpeed D (FT) Clarification CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL Titration pH 7.0 Elution buffer 25mM Acetate; pH 3.4
  • 47. 47 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) AEX QyuSpeed D (FT) Aggregate addition Clarification CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL Titration pH 7.0 Elution buffer 25mM Acetate; pH 3.4
  • 48. 48 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) Loading: 1041 mg/mL-BV MAb: 2.6 mg/mL Flow rate: 6 BV/min AEX QyuSpeed D (FT) Aggregate addition Clarification CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL Titration pH 7.0 Elution buffer 25mM Acetate; pH 3.4
  • 49. 49 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) Loading: 1041 mg/mL-BV MAb: 2.6 mg/mL Flow rate: 6 BV/min Titration pH 7.8 AEX QyuSpeed D (FT) Aggregate addition Clarification CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL Titration pH 7.0 Elution buffer 25mM Acetate; pH 3.4
  • 50. 50 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) Loading: 1041 mg/mL-BV MAb: 2.6 mg/mL Flow rate: 6 BV/min Titration pH 7.8 AEX QyuSpeed D (FT) Loading: 4156 mg/mL-BV MAb: 2.08 mg/ml Flow rate: 6 BV/min Aggregate addition Clarification CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL Titration pH 7.0 Elution buffer 25mM Acetate; pH 3.4
  • 51. 51 Combination CEX Prototype & AEX QyuSpeed D CEX prototype (FT)
  • 52. 52 Combination CEX Prototype & AEX QyuSpeed D CEX prototype (FT) Monomer 97.6 % Dimer / ≧Trimer 1.79 % / 0.56 % HCP 349 ppm Protein A 3.6 ppm Loading to CEX
  • 53. 53 Combination CEX Prototype & AEX QyuSpeed D CEX prototype (FT) Monomer 97.6 % Dimer / ≧Trimer 1.79 % / 0.56 % HCP 349 ppm Protein A 3.6 ppm Loading to CEX Flow Through of CEX - 88 % - 20 % - 83 % Monomer 99.66 % Dimer / ≧Trimer 0.28 % / < DL HCP 279 ppm Protein A 0.6 ppm Monomer Recovery: 95 %
  • 54. 54 Combination CEX Prototype & AEX QyuSpeed D CEX prototype (FT) Titration pH 7.8 AEX QyuSpeed D (FT) Monomer 97.6 % Dimer / ≧Trimer 1.79 % / 0.56 % HCP 349 ppm Protein A 3.6 ppm Loading to CEX Flow Through of CEX - 88 % - 20 % - 83 % Monomer 99.66 % Dimer / ≧Trimer 0.28 % / < DL HCP 279 ppm Protein A 0.6 ppm Monomer Recovery: 95 %
  • 55. 55 Combination CEX Prototype & AEX QyuSpeed D CEX prototype (FT) Titration pH 7.8 AEX QyuSpeed D (FT) Monomer 97.6 % Dimer / ≧Trimer 1.79 % / 0.56 % HCP 349 ppm Protein A 3.6 ppm Loading to CEX Flow Through of CEX Flow Through of AEX - 88 % - 20 % - 83 % Monomer 99.66 % Dimer / ≧Trimer 0.28 % / < DL HCP 279 ppm Protein A 0.6 ppm Monomer Recovery: 95 % Monomer 99.75 % Dimer / ≧Trimer 0.18 % / < DL HCP < 1 ppm Protein A 0.1 ppm Monomer Recovery: 99 % - 35 % - 99 % - 83 %
  • 56. 1) Pathogen Removal Filters Conclusion
  • 57. 57 Conclusion ü  Increasing use of membranes in DSP & Flow Through mode preferred
  • 58. 58 Conclusion ü  Increasing use of membranes in DSP & Flow Through mode preferred ü  QyuSpeed D for AEX: •  Unique grafted-chain & hollow fiber design •  Excellent binding capacity & salt tolerance for DNA, HCP, Virus removal •  Very flexible implementation: pre or post Protein A, pre or post CEX •  Single Use or Reusable
  • 59. 59 Conclusion ü  Increasing use of membranes in DSP & Flow Through mode preferred ü  QyuSpeed D for AEX: •  Unique grafted-chain & hollow fiber design •  Excellent binding capacity & salt tolerance for DNA, HCP, Virus removal •  Very flexible implementation: pre or post Protein A, pre or post CEX •  Single Use or Reusable ü  QyuSpeed Prototype for CEX: •  Unique grafted-chain & hollow fiber design •  Flow Through mode •  High aggregate removal & monomer recovery @ > 1000 g/L loading •  Single Use or Reusable
  • 60. 60 Conclusion ü  Increasing use of membranes in DSP & Flow Through mode preferred ü  QyuSpeed D for AEX: •  Unique grafted-chain & hollow fiber design •  Excellent binding capacity & salt tolerance for DNA, HCP, Virus removal •  Very flexible implementation: pre or post Protein A, pre or post CEX •  Single Use or Reusable ü  QyuSpeed Prototype for CEX: •  Unique grafted-chain & hollow fiber design •  Flow Through mode •  High aggregate removal & monomer recovery @ > 1000 g/L loading •  Single Use or Reusable ü  Excellent synergy of both QyuSpeed membranes !
  • 61. 61 Thank you to my Japanese colleagues ! Taniguchi-san Koguma-san Shirataki-san Acknowledgements
  • 62. 62 Thank you to my Japanese colleagues ! Taniguchi-san Koguma-san Shirataki-san And my European Colleagues here today ! Mathithas-san and Konstantin-san Acknowledgements
  • 63. 63 18th Planova Workshop ü  22nd & 23rd October 2015 in Athens, Greece ü  Technical presentations by our customers about their experience with Planova virus removal filters, BioOptimal TFF, QyuSpeed D ü  Social activities: discover of the ancient city & special entertainments in the evenings ü  Number of attendees: 200 ü  YOU ARE WELCOME TO REGISTER !! ü  www.ak-bio.com/planova-workshop/workshop-2015-athens/description/
  • 65. 65 1.3 m1.4 m Industrial References ü  2 customers using already QyuSpeed D modules 5L
  • 66. §  Impurities removal by AEX (DNA, HCP), §  Potential enhancement of Prot. A (very expensive step): better efficiency, easier regeneration, more cycles. 66 Protein A UFPlanova AIEX CIEX Centri- fugation Tangential MF Depth Filtration or 0.2 µm filtration AEX with QyuSpeed D or much reduced size Innovative Implementation: pre Prot. A
  • 67. Protein A UFPlanova AIEX CIEX Centri- fugation Tangential MF Depth Filtration or 0.2 µm filtration 67 AEX with QyuSpeed D or much reduced size Other (very) Innovative Implementation: cell culture harvesting/clarification
  • 68. Protein A UFPlanova AIEX CIEX Centri- fugation Tangential MF Depth Filtration or 0.2 µm filtration 3 actions in 1 single step: ü  Cell culture clarification (0.2 µm; TFF mode), ü  AEX chromatography (DNA, Virus & HCP removal), ü  “Protection” of Protein A. 68 AEX with QyuSpeed D or much reduced size Other (very) Innovative Implementation: cell culture harvesting/clarification
  • 70. 70 Feed solution: MAb (h-IgG1), 5 mg/mL, pI 8.4 Buffer: 15 mM Tris-HCl pH: 7.0 Loading: ~ 1000 mg/mL-membrane volume (BV) Flow rate: 6 BV/min Aggregate Removal vs. Cond.
  • 71. 71 Feed solution: MAb (h-IgG1), 5 mg/mL, pI 8.4 Buffer: 15 mM Tris-HCl pH: 7.0 Loading: ~ 1000 mg/mL-membrane volume (BV) Flow rate: 6 BV/min Conductivity (mS/cm) 1.4 2.6 4.7 Feed solution Monomer (%) 94.73 95.94 95.49 Dimer (%) 2.25 1.59 2.2 ≧ Trimer (%) 3.02 2.47 2.31 Aggregate Removal vs. Cond.
  • 72. 72 Aggregate Removal vs. Cond. 1.4 mS/cm 2.6 mS/cm 4.7 mS/cm
  • 73. 73 Conductivity (mS/cm) 1.4 2.6 4.7 Monomer recovery (%) 88.87 92.32 89.12 Flow Through (reduction %) Monomer (%) 97.42 99.48 98.59 Dimer (%) 1.34 (49) 0.39 (78) 1.03 (60) ≧ Trimer (%) 1.24 (65) 0.13 (95) 0.38 (86) Aggregate Removal vs. Cond. 1.4 mS/cm 2.6 mS/cm 4.7 mS/cm pH 7.0
  • 74. 74 Conductivity (mS/cm) 1.4 2.6 4.7 Monomer recovery (%) 88.87 92.32 89.12 Flow Through (reduction %) Monomer (%) 97.42 99.48 98.59 Dimer (%) 1.34 (49) 0.39 (78) 1.03 (60) ≧ Trimer (%) 1.24 (65) 0.13 (95) 0.38 (86) Aggregate Removal vs. Cond. 1.4 mS/cm 2.6 mS/cm 4.7 mS/cm
  • 75. 75 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) AEX QyuSpeed D (FT) Clarification CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL
  • 76. 76 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) AEX QyuSpeed D (FT) Clarification CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL Elution buffer 0.1M Citrate; pH 3.4
  • 77. 77 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) AEX QyuSpeed D (FT) Clarification CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL Buffer change 15 mM Tris-HCl pH 7.0; Cond. 1.4 mS/cm Elution buffer 0.1M Citrate; pH 3.4
  • 78. 78 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) AEX QyuSpeed D (FT) Aggregate addition Clarification CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL Buffer change 15 mM Tris-HCl pH 7.0; Cond. 1.4 mS/cm Elution buffer 0.1M Citrate; pH 3.4
  • 79. 79 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) Titration pH 7.8 AEX QyuSpeed D (FT) Aggregate addition Clarification CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL Buffer change 15 mM Tris-HCl pH 7.0; Cond. 1.4 mS/cm Elution buffer 0.1M Citrate; pH 3.4
  • 80. 80 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) Loading: 1067 mg/mL-MV MAb: 5.22 mg/mL Flow rate: 6 BV/min Titration pH 7.8 AEX QyuSpeed D (FT) Aggregate addition Clarification CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL Buffer change 15 mM Tris-HCl pH 7.0; Cond. 1.4 mS/cm Elution buffer 0.1M Citrate; pH 3.4
  • 81. 81 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) Loading: 1067 mg/mL-MV MAb: 5.22 mg/mL Flow rate: 6 BV/min Titration pH 7.8 AEX QyuSpeed D (FT) Loading: 4713 mg/mL-MV MAb: 3.80 mg/ml Flow rate: 6 BV/min Aggregate addition Clarification CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL Buffer change 15 mM Tris-HCl pH 7.0; Cond. 1.4 mS/cm Elution buffer 0.1M Citrate; pH 3.4
  • 82. 82 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) Loading: 1067 mg/mL-MV MAb: 5.22 mg/mL Flow rate: 6 BV/min Titration pH 7.8 AEX QyuSpeed D (FT) Loading: 4713 mg/mL-MV MAb: 3.80 mg/ml Flow rate: 6 BV/min Aggregate addition Clarification Monomer 97.77 % Dimer / ≧Trimer 1.32 % / 0.91 % HCP 390 ppm Protein A 0.5 ppm Loading to CEX CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL Buffer change 15 mM Tris-HCl pH 7.0; Cond. 1.4 mS/cm Elution buffer 0.1M Citrate; pH 3.4
  • 83. 83 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) Loading: 1067 mg/mL-MV MAb: 5.22 mg/mL Flow rate: 6 BV/min Titration pH 7.8 AEX QyuSpeed D (FT) Loading: 4713 mg/mL-MV MAb: 3.80 mg/ml Flow rate: 6 BV/min Aggregate addition Clarification Monomer 97.77 % Dimer / ≧Trimer 1.32 % / 0.91 % HCP 390 ppm Protein A 0.5 ppm Loading to CEX Flow Through of CEX - 79 % - 35 % CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL - 80 % Buffer change 15 mM Tris-HCl pH 7.0; Cond. 1.4 mS/cm Monomer 99.54 % Dimer / ≧Trimer 0.33 % / 0.14 % HCP 254 ppm Protein A 0.1 ppm Monomer Recovery: 87 % Elution buffer 0.1M Citrate; pH 3.4
  • 84. 84 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) Loading: 1067 mg/mL-MV MAb: 5.22 mg/mL Flow rate: 6 BV/min Titration pH 7.8 AEX QyuSpeed D (FT) Loading: 4713 mg/mL-MV MAb: 3.80 mg/ml Flow rate: 6 BV/min Aggregate addition Clarification Monomer 97.77 % Dimer / ≧Trimer 1.32 % / 0.91 % HCP 390 ppm Protein A 0.5 ppm Loading to CEX Flow Through of CEX Flow Through of AEX - 79 % - 35 % CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL - 80 % Buffer change 15 mM Tris-HCl pH 7.0; Cond. 1.4 mS/cm Monomer 99.54 % Dimer / ≧Trimer 0.33 % / 0.14 % HCP 254 ppm Protein A 0.1 ppm Monomer Recovery: 87 % Monomer 99.79 % Dimer / ≧Trimer 0.21 % / < DL HCP 6 ppm Protein A < 0.1 ppm Monomer Recovery: 99 % - 55 % - 98 % Elution buffer 0.1M Citrate; pH 3.4
  • 85. 85 Combination CEX Prototype & AEX QyuSpeed D 0 0.2 0.4 0.6 0.8 1 1.2 0.00 200.00 400.00 600.00 800.00 1000.00 C/C0 Load IgG(mg/mL-ad) CEX Monomer Dimer ≧Trimer HCP protein A 0 0.2 0.4 0.6 0.8 1 1.2 0 1000 2000 3000 4000 5000 C/C0 Load IgG(mg/mL-ad) AEX Monomer Dimer ≧Trimer HCP Monomer 97.77 % Dimer / ≧Trimer 1.32 % / 0.91 % HCP 390 ppm Protein A 0.5 ppm Loading to CEX Flow Through of CEX Flow Through of AEX - 79 % - 35 % - 80 % Monomer 99.54 % Dimer / ≧Trimer 0.33 % / 0.14 % HCP 254 ppm Protein A 0.1 ppm Monomer Recovery: 87 % Monomer 99.79 % Dimer / ≧Trimer 0.21 % / < DL HCP 6 ppm Protein A < 0.1 ppm Monomer Recovery: 99 % - 55 % - 98 %
  • 86. 86 Combination CEX Prototype & AEX QyuSpeed D Monomer 97.6 % Dimer / ≧Trimer 1.79 % / 0.56 % HCP 349 ppm Protein A 3.6 ppm Loading to CEX Flow Through of CEX Flow Through of AEX - 88 % - 20 % - 83 % Monomer 99.66 % Dimer / ≧Trimer 0.28 % / < DL HCP 279 ppm Protein A 0.6 ppm Monomer Recovery: 95 % Monomer 99.75 % Dimer / ≧Trimer 0.18 % / < DL HCP < 1 ppm Protein A 0.1 ppm Monomer Recovery: 99 % - 35 % - 99 % - 83 % 0 0.2 0.4 0.6 0.8 1 1.2 0 200 400 600 800 1000 C/C0 Load IgG(mg/mL-ad) CEX (NCX) Monomer Dimer >Trimer HCP Protein A 0 0.2 0.4 0.6 0.8 1 1.2 0 1000 2000 3000 4000 C/C0 Load IgG(mg/mL-ad) AEX (QSD) Monomer Dimer HCP Protein A
  • 87. 87 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) Loading: 1041 mg/mL-MV MAb: 2.6 mg/mL Flow rate: 6 BV/min Titration pH 7.8 AEX QyuSpeed D (FT) Loading: 4156 mg/mL-MV MAb: 2.08 mg/ml Flow rate: 6 BV/min Aggregate addition Clarification Monomer 97.6 % Dimer / ≧Trimer 1.79 % / 0.56 % HCP 349 ppm Protein A 3.6 ppm Loading to CEX CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL Titration pH 7.0 Elution buffer 25mM Acetate; pH 3.4
  • 88. 88 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) Loading: 1041 mg/mL-MV MAb: 2.6 mg/mL Flow rate: 6 BV/min Titration pH 7.8 AEX QyuSpeed D (FT) Loading: 4156 mg/mL-MV MAb: 2.08 mg/ml Flow rate: 6 BV/min Aggregate addition Clarification Monomer 97.6 % Dimer / ≧Trimer 1.79 % / 0.56 % HCP 349 ppm Protein A 3.6 ppm Loading to CEX Flow Through of CEX - 88 % - 20 % CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL - 83 % Monomer 99.66 % Dimer / ≧Trimer 0.28 % / < DL HCP 279 ppm Protein A 0.6 ppm Monomer Recovery: 95 % Titration pH 7.0 Elution buffer 25mM Acetate; pH 3.4
  • 89. 89 Combination CEX Prototype & AEX QyuSpeed D Protein A (BE) CEX prototype (FT) Loading: 1041 mg/mL-MV MAb: 2.6 mg/mL Flow rate: 6 BV/min Titration pH 7.8 AEX QyuSpeed D (FT) Loading: 4156 mg/mL-MV MAb: 2.08 mg/ml Flow rate: 6 BV/min Aggregate addition Clarification Monomer 97.6 % Dimer / ≧Trimer 1.79 % / 0.56 % HCP 349 ppm Protein A 3.6 ppm Loading to CEX Flow Through of CEX Flow Through of AEX - 88 % - 20 % CHO culture MAb (h-IgG1), pI 8.4, Titer < 1 mg/mL - 83 % Monomer 99.66 % Dimer / ≧Trimer 0.28 % / < DL HCP 279 ppm Protein A 0.6 ppm Monomer Recovery: 95 % Monomer 99.75 % Dimer / ≧Trimer 0.18 % / < DL HCP < 1 ppm Protein A 0.1 ppm Monomer Recovery: 99 % - 35 % - 99 % Titration pH 7.0 - 83 % Elution buffer 25mM Acetate; pH 3.4